Oncoclínicas Q2 2026 slides: cash flow rebounds amid supply crisis

Oncoclínicas, Brazil's leading oncology care provider, reported Q2 2026 results on August 17, revealing the significant impact of a medication supply crisis while also showcasing signs of operational stabilization. The company's shares surged nearly 30% to $1.00 following the presentation, driven by positive adjusted EBITDA and operating cash flow despite a 26% year-over-year revenue decline.

The main challenges came from medication shortages that disrupted patient care, with gross revenue falling to R$ 1.23 billion in the quarter, down from R$ 1.66 billion in the same period last year. However, the company secured a R$ 150 million private financing agreement to help normalize medication supply and set the stage for recovery.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.